Clinical Development International Licensing RNA 
Drug Discovery World
MARCH 7, 2023
For International Women’s Day, DDW’s Diana Spencer celebrates some of the women in leadership making an impact on the drug discovery and life sciences sector. She has over 15 years’ experience in corporate finance and restructurings, mergers and acquisitions, joint ventures and intellectual property licensing.
Drug Target Review
APRIL 9, 2024
In a previous study, we showed that these peptides decorate all cellular RNAs and thus impair the binding of RNA-binding proteins to RNA. Among other discoveries, the group developed inhibitors of the ATR kinase and showed their potential for cancer therapy.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Discovery World
JULY 2, 2024
An internal study performed recently, highlighted how Basel is outstanding in scientific collaboration with industry, measured via joint publications and at the same time how the local industry excels globally in the number of patents filed.” Biopôle Lausanne has been created to provide a focus for life sciences activity in the region.
The Pharma Data
JUNE 7, 2023
Acuitas’ LNP technology will support Bayer’s in vivo gene editing and protein replacement programs by specifically delivering RNA payloads to the desired target organ, the liver. This delivery technology protects the messenger RNA (mRNA) payload after administration allowing it to be safely and effectively delivered into cells.
Drug Discovery World
SEPTEMBER 14, 2023
Moreover, in July 2023, AstraZeneca and Vaxess Technologies commenced a collaboration for the evaluation of a novel RNA-based pandemic influenza prototype vaccine in patch format. Chief Development Officer and Executive Vice President, will be leaving Pfizer to pursue new opportunities outside the company.
Drug Discovery World
OCTOBER 16, 2023
A company within this ecosystem is STORM Therapeutics, a clinical stage biotechnology company creating novel small molecule therapies that inhibit RNA modifying enzymes (RME) for use in oncology and other diseases. The UK is additionally able to serve the US market with excellent international cultural and linguistic links.
The Pharma Data
DECEMBER 8, 2020
Now poised to advance a robust therapeutics pipeline to clinical development, Nuance will use the funds for ongoing R&D of existing products and business development of potential new assets. RayzeBio is also funneling cash into expanding its HQ in San Diego with plans to further develop internal R&D. .
Expert insights. Personalized for you.
246 
Let's personalize your content